Chapter 3 110 B C D H E 0 20 40 60 80 100 TIS+CD3 (n=28) TIS+CD20 (n=28) TIS+(TLS+LA) (n=28) TIS+TLS (n=28) TIS+PD-1T (n=27) TIS+IT-CD8 (n=28) TIS+CD8 (n=28) TIS+PD-L1 (n=28) TIS score 6.65 (n=28) DC 12 months Specificity (%) p=0.50 p=0.34 p=1.00 p=1.00 p=1.00 p=1.00 p=1.00 p=1.00 A 0 20 40 60 80 100 PD-1T+CD3 (n=42) PD-1T+CD20 (n=42) PD-1T+(TLS+LA) (n=42) PD-1T+TLS (n=42) PD-1T+TIS (n=27) PD-1T+IT-CD8 (n=42) PD-1T+CD8 (n=42) PD-1T+PD-L1 (n=42) PD-1T 90/ mm2 (n=42) Specificity (%) DC 12 months p=1.00 p=0.38 p=0.29 p=0.63 p=1.00 p=1.00 p=0.50 p=1.00 Training cohort PD n=43 DC 12m n=12 0.0 0.2 0.4 0.6 0.8 1.0 1.2 CD8 + IT-CD8 (score) *** PD n=22 DC 12m n=6 0.0 0.2 0.4 0.6 0.8 1.0 1.2 CD8 + TIS (score) ** Training cohort F PD n=31 DC 12m n=7 0.0 0.2 0.4 0.6 0.8 1.0 1.2 CD8 + TIS (score) ns Validation cohort PD n=61 DC 12m n=16 0.0 0.2 0.4 0.6 0.8 1.0 1.2 CD8 + IT-CD8 (score) * Validation cohort G PD n=33 DC 12m n=9 0 100 200 300 400 500 500 1000 1500 2000 PD-1T per mm2 ** Training cohort Training cohort PD n=22 DC 12m n=6 2 4 6 8 10 TIS (score) *
RkJQdWJsaXNoZXIy MTk4NDMw